Intuitive Surgical, Inc.
ISRG 6.5Price and target zones价格与目标区间
What the company does公司做什么
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung.
Read the full description查看完整介绍
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Products and services产品与服务 from the vendor summary — not yet written up来自供应商简介——尚未整理成文
- The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems
- Progressive learning pathways to support the use of its technology
- Infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring
Company facts公司资料
- Founded成立时间
- 1995
- Headquarters总部
- Sunnyvale, California
- Employees员工人数
- 17,021
- Industry行业
- Medical Instruments & Supplies
- Country国家
- United States
Investment thesis投资逻辑 from the watchlist来自关注列表
📋 Analyzed 8/27 — WATCH, first score. Razor/blade compounder (11,710 da Vinci systems +12%, rising ROIC 13.6%→14.8%, net cash) — but 2026 is the first year it faces FDA-authorized US rivals (Medtronic Hugo Dec-2025, J&J Ottava Jul-2026); "contested procedure share" went 0%→75.6% in a year.
Stock down ~40% from its ATH to roughly fair value. A live incumbent-side instance of [[pattern-console-lock-in-is-symmetric]]. FV $330-410. Entry $300-335. Trim 45x ttm (~$392).
8/27 分析——WATCH，首次评分 [6.5]。 剃刀/刀片复利机（11,710 台达芬奇系统 +12%，ROIC 13.6%→14.8% 上升，净现金）——但 2026 是它首次面对FDA 批准的美国对手（Medtronic Hugo 2025/12、J&J Ottava 2026/7）；"受争手术份额"一年内 0%→75.6%。 股价自历史高点跌约 40% 至大致公允。 是主机锁定对称性在位者一侧的现实实例。 FV $330-410。 入场 $300-335，减持 45x ttm（约 $392）。
Historical results历史业绩 past fiscal years — these values do not change过去财年——这些数值不会变动
Profit margins利润率 the share of revenue that stays as profit营收中留存为利润的比例
of every $1 of revenue每 $1 营收中的占比
- Return on equity净资产收益率
- 17%
- Revenue growth营收增长
- +18%
Competitive advantages竞争优势 from the thesis and the reports来自投资逻辑和报告
- A live incumbent-side instance of [[pattern-console-lock-in-is-symmetric]].
- Knowledge check python .mcp/kb.py find ISRG returned two live notes, both read and applied: - [[pattern-console-lock-in-is-symmetric]] — installed-console moats protect the incumbent for short outages but exclude it for years once a rival console lands in the slot.
- Net income grew faster than revenue every year (operating leverage from the installed base plus the da Vinci 5 mix shift).
- Moat & Competitive Advantage Quantitative base ROIC (roic.ai return_on_inv_capital ): 13.63% (FY2024) → 14.75% (FY2025), rising.
- Operating margin is also expanding: 28.1% (FY2024 annual) → 29.3% (FY2025 annual) → 33.6% (TTM, Yahoo snapshot) — margin trend supports "moat intact," not "moat eroding," on the numbers available today.